Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IMNM | ANALYST-UPGRADE | bullish | 4/10 | William Blair initiated coverage on Immunome Inc. (IMNM) with an Outperform rating on October 16, 2026, though no price | Oct 16, 2026 |
| SCNI | 6-K | bearish | 6/10 | Scinai Immunotherapeutics closed a $4.0 million private placement and warrant inducement transaction, issuing 2,458,334 | Oct 16, 2026 |
| MBRX | 8-K | neutral | 3/10 | Moleculin Biotech filed an 8-K on October 16, 2026, to furnish a corporate investor presentation (Exhibit 99.1) posted o | Oct 16, 2026 |
| ERAS | 8-K | neutral | 2/10 | Erasca announced the termination of COO Nicholas Chetwyn, Ph.D., effective November 2, 2026, as part of a leadership rea | Oct 16, 2026 |
| IMRN | 6-K | neutral | 3/10 | Immuron filed its Notice of 2026 Annual General Meeting and Proxy Form as a 6-K. The AGM will be held on 18 November 202 | Oct 16, 2026 |
| SCNI | PRESS-RELEASE | bearish | 5/10 | Scinai closed a $4.0M private placement and warrant inducement, issuing ~2.46M ADSs and warrants for up to ~5.0M additio | Oct 16, 2026 |
| CRIS | PRESS-RELEASE | bearish | 6/10 | Curis announced an $8.5 million private placement with existing healthcare-focused institutional investors, selling ~16. | Oct 16, 2026 |
| EBS | 8-K | neutral | 3/10 | Emergent BioSolutions announced that CFO Richard Lindahl will retire effective December 31, 2026, and will serve as an a | Oct 16, 2026 |
| ATNM | DEF 14A | neutral | 3/10 | Actinium Pharmaceuticals filed its definitive proxy statement for the 2026 Annual Meeting, seeking to re-elect directors | Oct 16, 2026 |
| IRWD | 8-K | neutral | 3/10 | Ironwood Pharmaceuticals announced a planned CEO transition: current CEO Thomas McCourt will retire effective December 3 | Oct 16, 2026 |
| TLSA | 6-K | neutral | 4/10 | Tiziana Life Sciences announced that the last patient has begun dosing in its Phase 2 trial of intranasal foralumab for | Oct 16, 2026 |
| RGNX | 8-K | neutral | 2/10 | Director Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new CEO role at another co | Oct 16, 2026 |
| GDTC | SC 13D/A | neutral | 3/10 | Chairman Choo Chee Kong filed an amended Schedule 13D reporting open-market purchases of 29,250 ordinary shares between | Oct 16, 2026 |
| PLUR | EFFECT | bearish | 5/10 | The SEC declared effective Pluri Inc.'s S-1 registration statement (File No. 333-299324) on October 15, 2026. This allow | Oct 16, 2026 |
| CTY | EFFECT | neutral | 5/10 | City Therapeutics, Inc. received SEC effectiveness for its S-1 registration statement (File No. 333-299117) on October 1 | Oct 16, 2026 |
| RLYB | EFFECT | neutral | 4/10 | The SEC declared effective Rallybio Corp's S-4 registration statement (File No. 333-297483) on October 15, 2026. This ef | Oct 16, 2026 |
| ENSC | 8-K/A | bearish | 7/10 | Ensysce Biosciences filed an amended 8-K (8-K/A) providing unaudited pro forma financial information for its August 5, 2 | Oct 15, 2026 |
| MESO | 6-K | bullish | 6/10 | Mesoblast reported a 44% increase in Ryoncil net revenue to $28M for the first fiscal quarter ended September 30, 2026, | Oct 15, 2026 |
| CTY | 3 | neutral | 3/10 | ARCH Venture Fund XII, L.P. and related parties filed initial statements of beneficial ownership (Form 3) for City Thera | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Tracy Zimmermann, Chief Scientific Officer of City Therapeutics, filed a Form 3 initial statement of beneficial ownershi | Oct 15, 2026 |
| LNAI | SC 13D/A | bearish | 6/10 | William Anderson Wittekind filed Amendment No. 25 to his Schedule 13D, reporting that his beneficial ownership of Lunai | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Keith Regnante filed a Form 3 initial statement of beneficial ownership upon becoming Chief Financial Officer of City Th | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Ron Philip filed a Form 3 initial statement of beneficial ownership with City Therapeutics, disclosing 59,878 stock opti | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Andrew C. Orth filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his position as Preside | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Sara Nochur filed a Form 3 initial statement of beneficial ownership, reporting a stock option grant for 59,878 shares a | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Robert Nelsen filed a Form 3 initial statement of beneficial ownership with City Therapeutics, Inc., disclosing indirect | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Baisong Mei filed a Form 3 initial statement of beneficial ownership with City Therapeutics, Inc., disclosing 228,743 sh | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | John Maraganore filed a Form 3 initial statement of beneficial ownership with City Therapeutics, Inc., reporting 859,933 | Oct 15, 2026 |
| CTY | 3 | neutral | 2/10 | Barry Greene filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting a stock option grant fo | Oct 15, 2026 |
| IDXX | COURT-RULING | neutral | 2/10 | The court granted IDEXX's motion to set aside an entry of default in a former employee's disability discrimination lawsu | Oct 15, 2026 |